HK1250636A1 - 用於治疗纤维症的短链脱氢酶活性的抑制剂 - Google Patents

用於治疗纤维症的短链脱氢酶活性的抑制剂 Download PDF

Info

Publication number
HK1250636A1
HK1250636A1 HK18110045.4A HK18110045A HK1250636A1 HK 1250636 A1 HK1250636 A1 HK 1250636A1 HK 18110045 A HK18110045 A HK 18110045A HK 1250636 A1 HK1250636 A1 HK 1250636A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
aryl
radical
group
substituted
Prior art date
Application number
HK18110045.4A
Other languages
English (en)
Chinese (zh)
Inventor
S‧马科维茨
S‧馬科維茨
S‧格尔森
A‧德赛
S‧格爾森
W‧J‧浩
A‧德賽
Original Assignee
卡斯西部储备大学
卡斯西部儲備大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 卡斯西部储备大学, 卡斯西部儲備大學 filed Critical 卡斯西部储备大学
Publication of HK1250636A1 publication Critical patent/HK1250636A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18110045.4A 2015-03-08 2016-03-08 用於治疗纤维症的短链脱氢酶活性的抑制剂 HK1250636A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562129885P 2015-03-08 2015-03-08
US62/129,885 2015-03-08
PCT/US2016/021374 WO2016144958A1 (en) 2015-03-08 2016-03-08 Inhibitors of short-chain dehydrogenase activity for treating fibrosis

Publications (1)

Publication Number Publication Date
HK1250636A1 true HK1250636A1 (zh) 2019-01-11

Family

ID=56879350

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110045.4A HK1250636A1 (zh) 2015-03-08 2016-03-08 用於治疗纤维症的短链脱氢酶活性的抑制剂

Country Status (8)

Country Link
US (3) US10945998B2 (cg-RX-API-DMAC7.html)
EP (1) EP3267995B1 (cg-RX-API-DMAC7.html)
JP (3) JP2018511581A (cg-RX-API-DMAC7.html)
CN (2) CN107921025A (cg-RX-API-DMAC7.html)
AU (3) AU2016229918B2 (cg-RX-API-DMAC7.html)
CA (1) CA2979203A1 (cg-RX-API-DMAC7.html)
HK (1) HK1250636A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016144958A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
WO2016144958A1 (en) 2015-03-08 2016-09-15 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
CA2870666A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
CA2927730A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
EP3283074A4 (en) * 2015-04-14 2018-12-05 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) * 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
JP7178360B2 (ja) 2017-04-07 2022-11-25 ケース ウエスタン リザーブ ユニバーシティ 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤
EP3630773A1 (en) * 2017-05-26 2020-04-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
JP7575952B2 (ja) 2019-01-08 2024-10-30 杏林製薬株式会社 15-pgdh阻害薬
WO2020160151A1 (en) 2019-01-31 2020-08-06 Kyorin Pharmaceutical Co., Ltd. 15-pgdh inhibitors
JP7677983B2 (ja) 2020-01-23 2025-05-15 マイオフォルテ セラピューティクス,インク. Pgdh阻害剤、およびその作製と使用の方法
AU2021224268A1 (en) * 2020-02-21 2022-09-15 Case Western Reserve University Compositions and methods for treating renal injury
CR20220654A (es) 2020-05-20 2023-08-24 Rodeo Therapeutics Corp Composiciones y métodos para modular la actividad de deshidrogenasas de cadena corta
WO2021252936A1 (en) * 2020-06-11 2021-12-16 The Board Of Trustees Of The Leland Stanford Junior University Rejuvenation of aged tissues and organs by inhibition of the pge2 degrading enzyme, 15-pgdh
EP4228650A4 (en) * 2020-10-15 2024-12-18 Myoforte Therapeutics Inc. INHALATED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF
WO2023076986A1 (en) * 2021-10-27 2023-05-04 The Board Of Trustees Of The Leland Stanford Junior University Regeneration or rejuvenation of tissues and organs
CN114875003B (zh) * 2022-04-06 2024-05-24 浙江大学 一种短链脱氢酶的突变体、编码基因及编码基因获得方法、突变体的应用
TW202434597A (zh) * 2022-11-14 2024-09-01 大陸商武漢人福創新藥物研發中心有限公司 抑制15-pgdh的化合物及其用途
CN118515655A (zh) * 2023-02-17 2024-08-20 武汉人福创新药物研发中心有限公司 亚砜类化合物及其用途
CN121772923A (zh) * 2023-06-28 2026-03-31 埃皮里姆生物股份有限公司 用于治疗与升高的15-pgdh相关的病况的间歇给药方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8405924L (sv) 1984-11-23 1986-05-24 Pharmacia Ab Nya azoforeningar
GB8709248D0 (en) 1987-04-16 1987-05-20 Wyeth John & Brother Ltd Azo compounds
US5445164A (en) 1993-05-11 1995-08-29 Gynetech, Inc. Cervical tissue sampling device
SE9303444D0 (sv) 1993-10-20 1993-10-20 Kabi Pharmacia Ab New use of prostaglandins
US6080772A (en) * 1995-06-07 2000-06-27 Sugen, Inc. Thiazole compounds and methods of modulating signal transduction
US6281227B1 (en) 1996-12-13 2001-08-28 Aventis Pharma Deutschland Gmbh Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
DE69823852T2 (de) 1997-02-04 2005-05-19 Johnstone, Murray A., Seattle Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
US6214533B1 (en) 1998-04-10 2001-04-10 Konica Corporation Thermally developable photosensitive material
US8068897B1 (en) 1999-03-01 2011-11-29 Gazdzinski Robert F Endoscopic smart probe and method
EP1080728A1 (en) * 1999-03-16 2001-03-07 Toray Industries, Inc. Prostaglandin ep4 receptor agonist and treatment method
AU7360700A (en) * 1999-09-09 2001-04-10 Androsolutions, Inc. Methods and compositions for preventing and treating urinary tract disorders
US7004913B1 (en) 2001-05-04 2006-02-28 Cdx Laboratories, Inc. Retractable brush for use with endoscope for brush biopsy
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
ATE375349T1 (de) 2002-08-02 2007-10-15 Merck & Co Inc Substituierte furo(2,3-b)pyridin derivate
FR2845000B1 (fr) 2002-09-27 2005-05-27 Oreal Utilisation d'un compose heterocyclique ou de l'un de ses sels pour stimuler ou induire la pousse des cheveux et/ou freiner leur chute
EP1594438B1 (fr) 2003-02-12 2013-07-17 L'Oréal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine déshydrogénase pour favoriser la pigmentation de la peau ou des phanères
ES2559779T3 (es) * 2003-08-29 2016-02-15 Vernalis (R&D) Limited Compuestos de pirimidotiofeno
JP2005325099A (ja) 2004-04-12 2005-11-24 Sankyo Co Ltd チエノピリジン誘導体
EP1781289A1 (en) * 2004-07-22 2007-05-09 PTC Therapeutics, Inc. Thienopyridines for treating hepatitis c
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
US20090118337A1 (en) * 2005-06-03 2009-05-07 Davis Pamela B Methods and compositions for treating inflammation
US20070071699A1 (en) 2005-06-28 2007-03-29 L'oreal Benzylidene-1,3-thiazolidine-2,4-dione compounds for promoting and/or inducing and/or stimulating the pigmentation of keratin materials and/or for limiting their depigmentation and/or whitening
US20070078175A1 (en) 2005-10-05 2007-04-05 L'oreal Administration of novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compounds for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof
DE602006016643D1 (de) 2005-12-20 2010-10-14 Richter Gedeon Nyrt THIENOÄ2,3-bÜPYRIDIN DERIVATE
AU2007243466B2 (en) 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
US8981060B2 (en) 2007-08-27 2015-03-17 Novelmed Therapuetics, Inc. Method of inhibiting complement activation with factor Bb specific antibodies
DE102007049451A1 (de) 2007-10-16 2009-04-23 Merck Patent Gmbh 5-Cyano-thienopyridine
JP2011512346A (ja) * 2008-02-15 2011-04-21 ノボビオン オイ クルクミンの可溶性錯体
US7629112B1 (en) * 2008-05-30 2009-12-08 Eastman Kodak Company Color photographic materials with yellow minimum density colorants
US20100093764A1 (en) 2008-10-13 2010-04-15 Devraj Chakravarty AMINES AND SULFOXIDES OF THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
EP2383263B1 (en) 2008-12-30 2014-04-16 Industry-academic Cooperation Foundation, Chosun University Novel thiazolidinedione derivative and use thereof
EP2308883A1 (en) 2009-10-05 2011-04-13 Centre National De La Recherche Scientifique New derivatives of thieno[2,3-b]pyridine and 5,6,7,8 tetrahydrothieno[2,3 b]quinoline in particular useful in the treatment of malaria
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
EP2806876A4 (en) * 2012-01-25 2016-03-02 Proteostasis Therapeutics Inc Proteasome activity enhancing compounds
WO2016144958A1 (en) 2015-03-08 2016-09-15 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
CA2870666A1 (en) 2012-04-16 2013-10-24 Case Western Reserve University Compositions and methods of modulating 15-pgdh activity
US9801863B2 (en) 2012-04-16 2017-10-31 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis
KR101244964B1 (ko) * 2012-05-30 2013-03-18 조선대학교산학협력단 15-히드록시프로스타글란딘 디히드로게나제 및 pge2 활성을 조절하는 황칠나무 추출물의 용도
WO2014160947A1 (en) 2013-03-29 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof
EP3525308A1 (en) 2013-07-10 2019-08-14 Revive Electronics LLC Apparatuses and methods for controlling power to electronic devices
CA2927730A1 (en) 2013-10-15 2015-05-07 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
GB201502020D0 (en) * 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
EP3283074A4 (en) 2015-04-14 2018-12-05 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
CA3031091A1 (en) 2016-07-18 2018-01-25 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
JP7178360B2 (ja) 2017-04-07 2022-11-25 ケース ウエスタン リザーブ ユニバーシティ 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤
JP2021134242A (ja) 2020-02-25 2021-09-13 株式会社アイティー技研 鉱物油精製方法及び装置
JP7574640B2 (ja) 2020-12-23 2024-10-29 株式会社リコー 画像処理装置、画像処理システム、方法およびプログラム

Also Published As

Publication number Publication date
AU2016229918B2 (en) 2020-10-29
US10945998B2 (en) 2021-03-16
JP7282067B2 (ja) 2023-05-26
EP3267995A4 (en) 2019-02-27
EP3267995B1 (en) 2025-10-08
JP2023103379A (ja) 2023-07-26
WO2016144958A1 (en) 2016-09-15
US20210283113A1 (en) 2021-09-16
AU2016229918A1 (en) 2017-09-28
JP2021038247A (ja) 2021-03-11
EP3267995A1 (en) 2018-01-17
AU2021200610B2 (en) 2022-09-15
JP2018511581A (ja) 2018-04-26
CN107921025A (zh) 2018-04-17
CN118059093A (zh) 2024-05-24
US20250295640A1 (en) 2025-09-25
AU2022287625A1 (en) 2023-02-02
AU2021200610A1 (en) 2021-03-04
CA2979203A1 (en) 2016-09-15
US20180064694A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
US20250295640A1 (en) Inhibitors of short-chain dehydrogenase activity for treating fibrosis
JP2018511581A5 (cg-RX-API-DMAC7.html)
US20260007642A1 (en) Inhibitors of short-chain dehydrogenase activity for promoting neurogenesis and inhibiting nerve cell death
JP6789542B2 (ja) 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
US20210094968A1 (en) Compositions and methods of modulating short-chain dehydrogenase activity
KR20220101071A (ko) 새로운 화합물
CN111132982A (zh) 调节短链脱氢酶活性的组合物和方法
WO2006080323A1 (ja) ヘテロ6員環化合物及びその用途
WO2014194209A1 (en) Substituted cyclopentenes as therapeutic agents